Here are the 10-K annual reports from Quantumzyme Corp (QTZM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QTZM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTZM filings page.
Quantumzyme Corp. (QTZM) files an amended Annual Report to update key disclosures. The amendment replaces the prior audit opinion from Fruci & Associates II, PLLC with an updated report that reflects final authorization, and adds $54,500 of stock-based compensation for CEO Naveen Krishnarao Kulkarni to the 2024 executive compensation table.
Quantumzyme is an early-stage enzyme engineering company focused on greener production of pharmaceutical ingredients, initially targeting Ibuprofen manufacturing through licensed biocatalysts rather than in-house production. The company has not yet generated revenue, operates with a single employee, and discloses substantial risks, including dependence on third-party manufacturers, significant competition, going concern uncertainty, and a dual-class capital structure that concentrates voting control. As of November 10, 2025, 38,962,050 common shares were outstanding, and non-affiliate equity value at the prior second fiscal quarter was about $4,327,050.
Quantumzyme Corp. (QTZM) filed its annual report for the year ended July 31, 2025. The company is a development-stage biotransformation business focused on engineered enzymes, with its first product aimed at greener ibuprofen API production. It plans to license the enzyme to manufacturers and pursue royalties while using third-party facilities for scale-up.
Management discloses a going concern risk and the need for additional capital to execute its plan. Governance is concentrated via dual-class preferred stock with 100 and 500 votes per share. The company reports one employee and shared office space costing about $500 per month. As of November 10, 2025, 38,962,050 common shares were outstanding; the aggregate market value of non‑affiliate equity was approximately $4,327,050 as of the last business day of the most recently completed second fiscal quarter. No material cybersecurity incidents were identified. Common stock is registered under Section 12(g); none under Section 12(b).